<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556022</url>
  </required_header>
  <id_info>
    <org_study_id>The ATHENA Trial</org_study_id>
    <nct_id>NCT01556022</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia</brief_title>
  <acronym>ATHENA</acronym>
  <official_title>Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, placebo-controlled, double blind safety and feasibility
      clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and feasibility of Adipose-Derived Regenerative Cells (ADRCs) delivered
      via an intramyocardial route in the treatment of chronic ischemic heart disease in patients
      who are not eligible for percutaneous or surgical revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent serious adverse events (SAEs), major adverse cardiac events (MACE), arrhythmia assessment, change in cardiac function and symptoms, and resource utilization</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Safety endpoints include:
Treatment emergent SAEs
Arrhythmia assessment via Holter monitoring
MACE defined as cardiac death and hospitalization for heart failure
Feasibility endpoints include:
Change in mVO2 at 6 months
Change in LVESV/LVEDV at 6 months
Change in ejection fraction at 6 months
Change in perfusion defect at 6 months
Resource utilization
Change in heart failure symptoms, angina, and quality of life through 12 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>ADRCs processed by the Celution System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringers and Subject's blood</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ADRCs processed by the Celution System</intervention_name>
    <description>Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.</description>
    <arm_group_label>ADRCs processed by the Celution System</arm_group_label>
    <other_name>ADRCs</other_name>
    <other_name>Intramyocardial injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Comparator: Lactated Ringer's and Subject's Blood</intervention_name>
    <description>Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.</description>
    <arm_group_label>Lactated Ringers and Subject's blood</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males or females 20-80 years of age

          2. Significant multi-vessel coronary artery disease not amenable to percutaneous or
             surgical revascularization in the target area

          3. CCS Angina Functional Class II-IV and/or NYHA Stages of Heart Failure Class II or III

          4. On maximal medical therapy for anginal symptoms and or heart failure symptoms

          5. Hemodynamic stability (Systolic Blood Pressure ≥ 90 mm/Hg, Heart Rate &lt; 110;
             Pulse-Oxygen &gt; 95)

          6. Ejection fraction ≤ 45

          7. Left ventricular wall thickness ≥ 8 mm at the target site for cell injection,
             confirmed by 2D contrast echo within 4 weeks prior to enrollment, free of thrombus

        Key Exclusion Criteria:

          1. Atrial fibrillation or flutter without a pace maker that guarantees a stable heart
             rate

          2. Unstable angina

          3. LV thrombus, as documented by echocardiography

          4. Planned staged treatment of CAD or other intervention on the heart

          5. Platelet count &lt; 100,000/mm3

          6. WBC &lt; 2,000/mm3

          7. TIA or stroke within 90 days prior to randomization

          8. ICD shock within 30 days of randomization

          9. Any condition requiring immunosuppressive medication

         10. A high-risk acute coronary syndrome (ACS) or a myocardial infarction within 60 days
             prior to randomization

         11. Revascularization within 60 days prior to randomization

         12. Inability to walk on a treadmill except for class IV angina patients who will be
             evaluated separately

         13. Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and /or alanine
             aminotransferase (ALT) &gt; 1.5 times the upper limit of normal range (x ULN) prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emerson Perin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Heart Institute, Houston, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute Foundation, Minneapolis, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic - Torrey Pines, Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital-Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Henry TD, Pepine CJ, Lambert CR, Traverse JH, Schatz R, Costa M, Povsic TJ, David Anderson R, Willerson JT, Kesten S, Perin EC. The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2017 Feb 1;89(2):169-177. doi: 10.1002/ccd.26601. Epub 2016 Sep 23.</citation>
    <PMID>27148802</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Chronic heart failure</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Adult stem cells</keyword>
  <keyword>Adipose derived regenerative cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

